Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18655741 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL18700457 | 0.94 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL18655742 | 0.94 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL18655754 | 0.90 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL18650598 | 0.90 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL18655737 | 0.90 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL11913026 | 0.88 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL18650599 | 0.86 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL17099889 | 0.85 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL17114311 | 0.85 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017494-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170096410-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-20170081285-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017494-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-20170096410-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-20170081285-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.